However, despite NT-proBNP measuring should be part of an updated “Good Clinical Practice” (GCP), this biomarker is rarely (or even never) tested in real-life daily clinical practice, even in T2DM patients often affected by multiple comorbidities, such as older age, obesity and arterial hypertension. Here, NPPB is linked to Hypertension.